NOAC Costs Weigh Heavy In Europe, Unmet Needs Remain
Makers of novel oral anticoagulants need to work on gaining real world data to prove their worth to European payers, as their INR testing benefit gets lost in administration.
You may also be interested in...
In Bristol/Pfizer's ARISTOPHANES real-world study, the rate of major bleeding with Eliquis was 46% lower than J&J/Bayer's Xarelto and 33% lower than Boehringer's Pradaxa.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.